Molecular Signatures that Predict Risk for Development of Hepatic Encephalopathy
AssigneesThe Regents of the University of California, The United States Government as represented by the Department of Veterans Affairs, University of Florida Research Foundation, Inc.
InventorsAmir Zarrinpar, Pieter C. Dorrestein, Ana Carolina Dantas Machado, Stephany Flores Ramos, Ali Zarrinpar
Life of this patent
Estimating the term…
Abstract
Methods for identifying biomarkers indicative of an increased risk for developing hepatic encephalopathy (HE) following transjugular intrahepatic portosystemic shunting (TIPS) are provided. Methods include determining whether the subject has a decreased level of metabolites following transjugular intrahepatic portosystemic shunting (TIPS), and/or determining a level of intrahepatic shunting in the subject. Methods for preventing and treating a subject having or at risk of having HE identified by the methods disclosed.
Claims17
A method of identifying a subject with an increased risk of developing hepatic encephalopathy (HE) comprising:
- determining whether the subject has a decreased level of metabolites following transjugular intrahepatic portosystemic shunting (TIPS);
- wherein a decreased level of metabolites is indicative of an increased risk of developing HE.
A method of identifying a subject with an increased risk of developing hepatic encephalopathy (HE) comprising:
- determining a level of intrahepatic shunting in the subject;
- wherein a low level of intrahepatic shunting is indicative of an increased risk of developing HE.
A method of identifying changes in metabolites in cirrhotic subjects undergoing transjugular intrahepatic portosystemic shunting (TIPS) comprising:
- collecting a pre-TIPS peripheral vein (PIV) blood sample and a pre-TIPS hepatic vein (HV) blood sample;
- collecting a post-TIPS PIV blood sample and a post-TIPS HV blood sample;
- comparing metabolites in the pre-TIPS PIV blood sample and the pre-TIPS HV blood sample with metabolites in the post-TIPS PIV blood sample and the post-TIPS HV blood sample;
- and
- identifying changes in metabolites through the comparison of the pre-TIPS PIV blood sample and the pre-TIPS HV blood sample with the post-TIPS PIV blood sample and the post-TIPS HV blood sample.
A method of identifying biomarkers indicating an increased risk of developing hepatic encephalopathy (HE) comprising:
- identifying a level of a bile acid in a subject before and after the subject undergoes transjugular intrahepatic portosystemic shunting (TIPS);
- wherein the subject has an increased risk of developing HE when a level of the bile acid following TIPS is less than a level of the bile acid before TIPS.
A method of preventing or treating hepatic encephalopathy in a subject following transjugular intrahepatic portosystemic shunting (TIPS) comprising:
- increasing a level of metabolites in the subject following TIPS;
- wherein increasing the level of metabolites reduces the subject's risk for developing HE.
Dependencies are inferred from the claim text.